Selected research
Industry Research
Diabetic Therapeutic Drugs Industry Research Report 2026
Market perspective
The global Diabetic Therapeutic Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Diabetic Therapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Diabetic Therapeutic Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Diabetic Therapeutic Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Diabetic Therapeutic Drugs include Arbutus Biopharma, AstraZeneca, Belrose Pharma, Dong-A ST, Eisai, F. Hoffmann-La Roche, Mitsubishi Tanabe Pharma, Novo Nordisk and Perle Biosciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Diabetic Therapeutic Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Diabetic Therapeutic Drugs Market by Company
Arbutus Biopharma
AstraZeneca
Belrose Pharma
Dong-A ST
Eisai
F. Hoffmann-La Roche
Mitsubishi Tanabe Pharma
Novo Nordisk
Perle Biosciences
Sun Pharma
Pfizer
Eli Lilly
Merck
Novartis
Sanofi
Takeda Pharmaceuticals
Diabetic Therapeutic Drugs Segment by Type
Insulin Therapies
Non-Insulin Therapies
Diabetic Therapeutic Drugs Segment by Application
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Diabetic Therapeutic Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Therapeutic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diabetic Therapeutic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Therapeutic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Diabetic Therapeutic Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Diabetic Therapeutic Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Diabetic Therapeutic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Insulin Therapies
- Non-Insulin Therapies
Applications
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
Companies covered
- Arbutus Biopharma
- AstraZeneca
- Belrose Pharma
- Dong-A ST
- Eisai
- F. Hoffmann-La Roche
- Mitsubishi Tanabe Pharma
- Novo Nordisk
- Perle Biosciences
- Sun Pharma
- Pfizer
- Eli Lilly
- Merck
- Novartis
- Sanofi
- Takeda Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Diabetic Therapeutic Drugs Market Size (2021-2032)
- 2.2.2 Global Diabetic Therapeutic Drugs Sales (2021-2032)
- 2.2.3 Global Diabetic Therapeutic Drugs Market Average Price (2021-2032)
- 2.3 Diabetic Therapeutic Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Insulin Therapies
- 2.3.3 Non-Insulin Therapies
- 2.4 Diabetic Therapeutic Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Type 1 Diabetes
- 2.4.3 Type 2 Diabetes
- 2.4.4 Gestational Diabetes
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Diabetic Therapeutic Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Diabetic Therapeutic Drugs Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Diabetic Therapeutic Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Diabetic Therapeutic Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Diabetic Therapeutic Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Diabetic Therapeutic Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Diabetic Therapeutic Drugs, Product Type & Application
- 3.8 Global Manufacturers of Diabetic Therapeutic Drugs, Established Date
- 3.9 Global Diabetic Therapeutic Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Arbutus Biopharma
- 4.1.1 Arbutus Biopharma Company Information
- 4.1.2 Arbutus Biopharma Business Overview
- 4.1.3 Arbutus Biopharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Arbutus Biopharma Diabetic Therapeutic Drugs Product Portfolio
- 4.1.5 Arbutus Biopharma Recent Developments
- 4.2 AstraZeneca
- 4.2.1 AstraZeneca Company Information
- 4.2.2 AstraZeneca Business Overview
- 4.2.3 AstraZeneca Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AstraZeneca Diabetic Therapeutic Drugs Product Portfolio
- 4.2.5 AstraZeneca Recent Developments
- 4.3 Belrose Pharma
- 4.3.1 Belrose Pharma Company Information
- 4.3.2 Belrose Pharma Business Overview
- 4.3.3 Belrose Pharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Belrose Pharma Diabetic Therapeutic Drugs Product Portfolio
- 4.3.5 Belrose Pharma Recent Developments
- 4.4 Dong-A ST
- 4.4.1 Dong-A ST Company Information
- 4.4.2 Dong-A ST Business Overview
- 4.4.3 Dong-A ST Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Dong-A ST Diabetic Therapeutic Drugs Product Portfolio
- 4.4.5 Dong-A ST Recent Developments
- 4.5 Eisai
- 4.5.1 Eisai Company Information
- 4.5.2 Eisai Business Overview
- 4.5.3 Eisai Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Eisai Diabetic Therapeutic Drugs Product Portfolio
- 4.5.5 Eisai Recent Developments
- 4.6 F. Hoffmann-La Roche
- 4.6.1 F. Hoffmann-La Roche Company Information
- 4.6.2 F. Hoffmann-La Roche Business Overview
- 4.6.3 F. Hoffmann-La Roche Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 F. Hoffmann-La Roche Diabetic Therapeutic Drugs Product Portfolio
- 4.6.5 F. Hoffmann-La Roche Recent Developments
- 4.7 Mitsubishi Tanabe Pharma
- 4.7.1 Mitsubishi Tanabe Pharma Company Information
- 4.7.2 Mitsubishi Tanabe Pharma Business Overview
- 4.7.3 Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Product Portfolio
- 4.7.5 Mitsubishi Tanabe Pharma Recent Developments
- 4.8 Novo Nordisk
- 4.8.1 Novo Nordisk Company Information
- 4.8.2 Novo Nordisk Business Overview
- 4.8.3 Novo Nordisk Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Novo Nordisk Diabetic Therapeutic Drugs Product Portfolio
- 4.8.5 Novo Nordisk Recent Developments
- 4.9 Perle Biosciences
- 4.9.1 Perle Biosciences Company Information
- 4.9.2 Perle Biosciences Business Overview
- 4.9.3 Perle Biosciences Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Perle Biosciences Diabetic Therapeutic Drugs Product Portfolio
- 4.9.5 Perle Biosciences Recent Developments
- 4.10 Sun Pharma
- 4.10.1 Sun Pharma Company Information
- 4.10.2 Sun Pharma Business Overview
- 4.10.3 Sun Pharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sun Pharma Diabetic Therapeutic Drugs Product Portfolio
- 4.10.5 Sun Pharma Recent Developments
- 4.11 Pfizer
- 4.11.1 Pfizer Company Information
- 4.11.2 Pfizer Business Overview
- 4.11.3 Pfizer Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer Diabetic Therapeutic Drugs Product Portfolio
- 4.11.5 Pfizer Recent Developments
- 4.12 Eli Lilly
- 4.12.1 Eli Lilly Company Information
- 4.12.2 Eli Lilly Business Overview
- 4.12.3 Eli Lilly Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Eli Lilly Diabetic Therapeutic Drugs Product Portfolio
- 4.12.5 Eli Lilly Recent Developments
- 4.13 Merck
- 4.13.1 Merck Company Information
- 4.13.2 Merck Business Overview
- 4.13.3 Merck Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Merck Diabetic Therapeutic Drugs Product Portfolio
- 4.13.5 Merck Recent Developments
- 4.14 Novartis
- 4.14.1 Novartis Company Information
- 4.14.2 Novartis Business Overview
- 4.14.3 Novartis Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Novartis Diabetic Therapeutic Drugs Product Portfolio
- 4.14.5 Novartis Recent Developments
- 4.15 Sanofi
- 4.15.1 Sanofi Company Information
- 4.15.2 Sanofi Business Overview
- 4.15.3 Sanofi Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Sanofi Diabetic Therapeutic Drugs Product Portfolio
- 4.15.5 Sanofi Recent Developments
- 4.16 Takeda Pharmaceuticals
- 4.16.1 Takeda Pharmaceuticals Company Information
- 4.16.2 Takeda Pharmaceuticals Business Overview
- 4.16.3 Takeda Pharmaceuticals Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Takeda Pharmaceuticals Diabetic Therapeutic Drugs Product Portfolio
- 4.16.5 Takeda Pharmaceuticals Recent Developments
5 Global Diabetic Therapeutic Drugs Market Scenario by Region
- 5.1 Global Diabetic Therapeutic Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Diabetic Therapeutic Drugs Sales by Region: 2021-2032
- 5.2.1 Global Diabetic Therapeutic Drugs Sales by Region: 2021-2026
- 5.2.2 Global Diabetic Therapeutic Drugs Sales by Region: 2027-2032
- 5.3 Global Diabetic Therapeutic Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Diabetic Therapeutic Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Diabetic Therapeutic Drugs Revenue by Region: 2027-2032
- 5.4 North America Diabetic Therapeutic Drugs Market Facts & Figures by Country
- 5.4.1 North America Diabetic Therapeutic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Diabetic Therapeutic Drugs Sales by Country (2021-2032)
- 5.4.3 North America Diabetic Therapeutic Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Diabetic Therapeutic Drugs Market Facts & Figures by Country
- 5.5.1 Europe Diabetic Therapeutic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Diabetic Therapeutic Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Diabetic Therapeutic Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Diabetic Therapeutic Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Diabetic Therapeutic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Diabetic Therapeutic Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Diabetic Therapeutic Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Diabetic Therapeutic Drugs Market Facts & Figures by Country
- 5.7.1 South America Diabetic Therapeutic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Diabetic Therapeutic Drugs Sales by Country (2021-2032)
- 5.7.3 South America Diabetic Therapeutic Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Diabetic Therapeutic Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Diabetic Therapeutic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Diabetic Therapeutic Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Diabetic Therapeutic Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Diabetic Therapeutic Drugs Sales by Type (2021-2032)
- 6.1.1 Global Diabetic Therapeutic Drugs Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Diabetic Therapeutic Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Diabetic Therapeutic Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Diabetic Therapeutic Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Diabetic Therapeutic Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Diabetic Therapeutic Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Diabetic Therapeutic Drugs Sales by Application (2021-2032)
- 7.1.1 Global Diabetic Therapeutic Drugs Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Diabetic Therapeutic Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Diabetic Therapeutic Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Diabetic Therapeutic Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Diabetic Therapeutic Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Diabetic Therapeutic Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Diabetic Therapeutic Drugs Value Chain Analysis
- 8.1.1 Diabetic Therapeutic Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Diabetic Therapeutic Drugs Production Mode & Process
- 8.2 Diabetic Therapeutic Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Diabetic Therapeutic Drugs Distributors
- 8.2.3 Diabetic Therapeutic Drugs Customers
9 Global Diabetic Therapeutic Drugs Analyzing Market Dynamics
- 9.1 Diabetic Therapeutic Drugs Industry Trends
- 9.2 Diabetic Therapeutic Drugs Industry Drivers
- 9.3 Diabetic Therapeutic Drugs Industry Opportunities and Challenges
- 9.4 Diabetic Therapeutic Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst